Tests benserazide in adults with beta thalassemia intermedia or sickle cell disease
Tests an oral drug to raise fetal hemoglobin in blood disease patients.
Key facts
- Who runs it
- Phoenicia BioScience
- Where
- Boston, New York, Oakland, and Weston, United StatesSee the 4 sitesAlso in 1 other country, 1 site
- Trial code
- Registry title
- The BENeFiTS Trial in Beta Thalassemia Intermedia
- Status
- Enrolling by invitation
- Phase
- Phase 1/2
- People taking part
- 36 people, planned
- Started
- 5 Oct 2020
- Planned end
- 28 Feb 2026
- Type of study
- Interventional, 5 groups
- Treatments tested
- Benserazide Only Product
- Record updated
- 15 August 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with beta thalassemia intermedia (non-transfusion dependent) or sickle cell disease. It tests the oral drug benserazide.
- Age
- Over 18 years
- Sex
- Men and women can join.
- Disease stage
- Beta thalassemia intermedia (non-transfusion dependent) with at least one documented beta thalassemia mutation, including HbE beta thalassemia, or an established diagnosis of sickle cell disease.
- Earlier treatment
- No red blood cell transfusion within 2 months before the study drug, and not in a chronic transfusion program. No erythropoiesis stimulating agents within 90 days, and no other investigational systemic therapy within 30 days.
- Biomarker or test result
- Average of 2 total hemoglobin (Hgb) levels between 6.0 and 10.0 g/dL in the preceding 6 months.
Main reasons for not taking part
- Pulmonary hypertension requiring oxygen therapy
- Known infection with HIV or untreated hepatitis C
- Currently pregnant or breast feeding a child
- Taking monoamine oxidase inhibitors
- Narrow angle glaucoma, or osteoporosis or osteomalacia with a fragility fracture
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Beta thalassemia intermedia (BTI) or (NTDT, Non-Transfusion Dependent Thalassemia) with at least one documented beta thalassemia mutation, including HbE beta thalassemia or an established diagnosis of sickle cell disease
- >18 years of age at time of consent
- Average of 2 total hemoglobin (Hgb) levels between 6.0 and 10.0 g/dL in the preceding 6 months
- Able and willing to give consent and comply with all study procedures
- If female and of childbearing potential, must have a documented negative pregnancy test prior to entry and agree to use one or more locally medically accepted methods of contraception
Who cannot take part
- Red blood cell (RBC) transfusion within 2 months prior to administration of study medication
- Fever > 38.5°C in the week prior to first administration of study medication
- Received other investigational systemic therapy within 30 days prior to first dose
- Known current drug or alcohol abuse
- Taking monoamine oxidase inhibitors
- Pulmonary hypertension requiring oxygen therapy
- Known infection with HIV or hepatitis C (untreated)
- History of osteoporosis or osteomalacia with a fragility fracture
- Transaminases > 3 times upper limit of institution normal (ULN)
- Total and direct bilirubin > 3 times institution ULN unless due solely to hemolysis
- Participating in a chronic transfusion program
- Use of erythropoiesis stimulating agents within 90 days of first dose
- Narrow angle glaucoma
- Currently pregnant or breast feeding a child
- Other co-morbidity that substantially increases subject risk for the study per Investigator discretion
Where in United States
Also in 1 other country, 1 site
- Massachusetts General HospitalBoston, United StatesEnrolling by invitation
- Weil Cornell MedicineNew York, United StatesEnrolling by invitation
- UCSF Benioff Children's Hospital at OaklandOakland, United StatesEnrolling by invitation
- Susan PerrineWeston, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
Beta-thalassemias and hemoglobinopathies are serious inherited blood diseases caused by abnormal or deficiency of beta A chains of hemoglobin, the protein in red blood cells which delivers oxygen throughout the body.The diseases are characterized by hemolytic anemia, organ damage, and early mortality without treatment. Increases in another type of (normal) hemoglobin, fetal globin (HbF), which is normally silenced in infancy, reduces anemia and morbidity. Even incremental augmentation of fetal globin is established to reduce red blood cell pathology, anemia, certain complications, and to improve survival.
Read full original descriptionShow less
This trial will evaluate an oral drug discovered in a high throughput screen, which increases fetal globin protein (HbF and red blood cells expressing HbF)and messenger ribonucleic acid (mRNA) to high levels in anemic nonhuman primates and in transgenic mice. The study drug acts by suppressing 4 repressors of the fetal globin gene promoter in progenitor cells from patients. The drug has been used for 50 years in a combination product for different actions - to enhance half-life and reduce side effects of a different active drug- and is considered safe for long-term use.
This trial will first evaluate 3 dose levels in small cohorts of nontransfused patients with beta thalassemia intermedia. The most active dose will then be evaluated in larger subject groups with beta thalassemia and other hemoglobinopathies, such as sickle cell disease.
The 5 groups in the trial
- Low doseTreatment being tested
A low dose, by mouth, once per day, on Monday, Wednesday, and Friday for 12 weeks
Treatment: Benserazide Only Product
- Middle doseTreatment being tested
A middle dose, by mouth, once per day, on Monday, Wednesday, and Friday, for 12 weeks
Treatment: Benserazide Only Product
- High dose 3 days per weekTreatment being tested
Highest dose, by mouth, once per day, on Monday, Wednesday, and Friday, for 12 to 24 weeks
Treatment: Benserazide Only Product
- High dose 5 days per weekTreatment being tested
The highest dose, by mouth once per day on 5 days per week for 24 weeks
Treatment: Benserazide Only Product
- Sickle Cell Disease ArmTreatment being tested
The most active dose given once per day on the most active regimen for up 24 weeks
Treatment: Benserazide Only Product
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1b Sequential Open Label Dose-Ranging Study of Safety, Pharmacokinetics, and Preliminary Activity of Benserazide in Subjects With Beta Thalassemia Intermedia and Sickle Cell Disease
- Plain-language title
- Tests benserazide in adults with beta thalassemia intermedia or sickle cell diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 15 August 2025